The pharmaceutical company announced the pricing of a public stock offering. It's wisely taking advantage of a soaring stock price to raise cash ahead of a crucial market launch.
News & Analysis: Intra-Cellular Therapies
The company's first FDA-approved product could be a big hit.
The stock market posted gains to start the holiday week.
The FDA approved the company's schizophrenia drug candidate.
Investors expect stock-moving news from all of these drugmakers before the end of 2019.
FDA announcements can make or break a stock. These four events are the most important ones this month.
This is your last chance to buy these companies' stocks before the Food and Drug Administration weighs in on the fates of their key candidate treatments.
The remaining weeks of December are chock-full of clinical trial results and FDA approval decisions that savvy investors can take advantage of.
ITCI earnings call for the period ending September 30, 2019.
Down over 18%, the biotech bounces back.